GlassScriptPhysician profile
Amanda Pleimann-King
NPI 1659722155
$1,878.74
in general payments reported to CMS, 2019-2025
23 companies · $580 in 2025
The $580 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.14 · 2022: $604 · 2023: $182 · 2024: $474 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,217 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,216.51 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $416.91 | 2022-2025 | |
| Lilly USA, LLC | $272.20 | 2022-2025 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $153.83 | 2024-2025 | |
| Gilead Sciences, INC. | $149.89 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $132.06 | 2024-2025 | |
| Novo Nordisk INC | $126.37 | 2023-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $88.78 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Exact Sciences Corporation | $70.78 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.17 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $62.40 | 2022-2025 | Farxiga, Breztri |
| Philips North America LLC | $60.63 | 2025 | Encore |
| Amgen INC. | $45.47 | 2024-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $35.23 | 2024 | Veozah |
| Idorsia Pharmaceuticals US INC | $27.20 | 2022-2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $22.02 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $21.51 | 2025 | Yupelri |
| Depuy Synthes Sales INC. | $21.33 | 2019 | |
| Verona Pharma, INC. | $20.03 | 2025 | Ohtuvayre |
| Dexcom, INC. | $18.74 | 2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $18.04 | 2023 | |
| Rhodes Pharmaceuticals L.P. | $17.81 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.75 | 2025 | Voquezna |
| Paratek Pharmaceuticals, INC. | $15.59 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Pleimann-King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.